BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/20/2026 11:00:23 AM | Browse: 18 | Download: 4
Publication Name World Journal of Hepatology
Manuscript ID 128445
DOI 10.4254/wjh.128445
Country United Kingdom
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies
Manuscript Source Unsolicited Manuscript
All Author List Shamaela Mashneil, Hamna Salimi, Zaw Myo Aung, Fatma Elsayed, Mohammad Malik and Prakash Gupta
Funding Agency and Grant Number
Corresponding Author Shamaela Mashneil, Department of Gastroenterology and Hepatology, Milton Keynes University Hospital, Standing Way, Milton Keynes MK6 5LD, United Kingdom. s_mashneil@yahoo.com
Key Words Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Gut-liver axis; Gut microbiome; Dysbiosis; Intestinal permeability; Bile acids; Farnesoid X receptor; Short-chain fatty acids; Faecal microbiota transplantation
Core Tip The gut-liver axis is implicated in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH), but much mechanistic evidence is preclinical. Dysbiosis, increased intestinal permeability, altered bile-acid signaling and changes in microbial metabolites (short-chain fatty acids, endogenous ethanol, trimethylamine N-oxide, and indoles) are associated with disease in humans, without proof of causality. Lifestyle change has the strongest clinical support; probiotics, synbiotics, and faecal microbiota transplantation have small, mixed trials; engineered bacteria and bacteriophage therapy are preclinical. No microbial or metabolite biomarker is validated for risk stratification, and the approved MASH drugs resmetirom and semaglutide are not microbiome-targeted.
Citation Mashneil S, Salimi H, Aung ZM, Elsayed F, Malik M, Gupta P. Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies. World J Hepatol 2026; In press
PDF 128445-in-press.pdf
ISSN 1948-5182 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com